Skip to main content
Top

Open Access 03-01-2024 | Original Paper

Healthcare resource utilisation and associated costs after low-risk pulmonary embolism: pre-specified analysis of the Home Treatment of Pulmonary Embolism (HoT-PE) study

Authors: Ioannis T. Farmakis, Klaus Kaier, Lukas Hobohm, Katharina Mohr, Luca Valerio, Stefano Barco, Stavros V. Konstantinides, Harald Binder

Published in: Clinical Research in Cardiology

Login to get access

Abstract

Background

Pulmonary embolism (PE) and its sequelae impact healthcare systems globally. Low-risk PE patients can be managed with early discharge strategies leading to cost savings, but post-discharge costs are undetermined.

Purpose

To define healthcare resource utilisation and overall costs during follow-up of low-risk PE.

Methods

We used an incidence-based, bottom–up approach and calculated direct and indirect costs over 3-month follow-up after low-risk PE, with data from the Home Treatment of Patients with Low-Risk Pulmonary Embolism (HoT-PE) cohort study.

Results

Average 3-month costs per patient having suffered low-risk PE were 7029.62 €; of this amount, 4872.93 € were associated with PE, accounting to 69.3% of total costs. Specifically, direct costs totalled 3019.33 €, and of those, 862.64 € (28.6%) were associated with PE. Anticoagulation (279.00 €), rehospitalisations (296.83 €), and ambulatory visits (194.95 €) comprised the majority of the 3-month direct costs. The remaining costs amounting to 4010.29 € were indirect costs due to loss of productivity.

Conclusion

In a patient cohort with acute low-risk PE followed over 3 months, the majority of costs were indirect costs related to productivity loss, whereas direct, PE-specific post-discharge costs were low. Effective interventions are needed to reduce the burden of PE and associated costs, especially those related to productivity loss.

Graphical abstract

Literature
1.
go back to reference Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ et al (2014) Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 34(11):2363–2371CrossRefPubMed Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ et al (2014) Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 34(11):2363–2371CrossRefPubMed
2.
go back to reference Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE (2016) European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 115(4):800–808CrossRefPubMed Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE (2016) European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 115(4):800–808CrossRefPubMed
3.
go back to reference Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603CrossRefPubMed Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603CrossRefPubMed
4.
go back to reference Wendelboe AM, Campbell J, Ding K, Bratzler DW, Beckman MG, Reyes NL et al (2021) Incidence of venous thromboembolism in a racially diverse population of Oklahoma County, Oklahoma. Thromb Haemost 121(6):816–825CrossRefPubMedPubMedCentral Wendelboe AM, Campbell J, Ding K, Bratzler DW, Beckman MG, Reyes NL et al (2021) Incidence of venous thromboembolism in a racially diverse population of Oklahoma County, Oklahoma. Thromb Haemost 121(6):816–825CrossRefPubMedPubMedCentral
5.
go back to reference Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S et al (2020) Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO mortality database. Lancet Respir Med 8(3):277–287CrossRefPubMed Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S et al (2020) Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO mortality database. Lancet Respir Med 8(3):277–287CrossRefPubMed
6.
go back to reference Farmakis IT, Keller K, Barco S, Konstantinides SV, Hobohm L (2022) From acute pulmonary embolism to post-pulmonary embolism sequelae. Vasa 52:29–37CrossRefPubMed Farmakis IT, Keller K, Barco S, Konstantinides SV, Hobohm L (2022) From acute pulmonary embolism to post-pulmonary embolism sequelae. Vasa 52:29–37CrossRefPubMed
8.
go back to reference Farmakis IT, Barco S, Mavromanoli AC, Agnelli G, Cohen AT, Giannakoulas G et al (2022) Cost-of-illness analysis of long-term health care resource use and disease burden in patients with pulmonary embolism: insights from the PREFER in VTE registry. J Am Heart Assoc 14:e027514CrossRef Farmakis IT, Barco S, Mavromanoli AC, Agnelli G, Cohen AT, Giannakoulas G et al (2022) Cost-of-illness analysis of long-term health care resource use and disease burden in patients with pulmonary embolism: insights from the PREFER in VTE registry. J Am Heart Assoc 14:e027514CrossRef
9.
go back to reference Becattini C, Agnelli G, Maggioni AP, Dentali F, Fabbri A, Enea I et al (2023) Contemporary management and clinical course of acute pulmonary embolism: the COPE study. Thromb Haemost 123:613–626CrossRefPubMedPubMedCentral Becattini C, Agnelli G, Maggioni AP, Dentali F, Fabbri A, Enea I et al (2023) Contemporary management and clinical course of acute pulmonary embolism: the COPE study. Thromb Haemost 123:613–626CrossRefPubMedPubMedCentral
10.
go back to reference Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E et al (2020) Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 41(4):509–518CrossRefPubMed Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E et al (2020) Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 41(4):509–518CrossRefPubMed
11.
go back to reference Roy P-M, Penaloza A, Hugli O, Klok FA, Arnoux A, Elias A et al (2021) Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. Eur Heart J 42(33):3146–3157CrossRefPubMedPubMedCentral Roy P-M, Penaloza A, Hugli O, Klok FA, Arnoux A, Elias A et al (2021) Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. Eur Heart J 42(33):3146–3157CrossRefPubMedPubMedCentral
12.
go back to reference Barco S, Schmidtmann I, Ageno W, Anusic T, Bauersachs RM, Becattini C et al (2021) Survival and quality of life after early discharge in low-risk pulmonary embolism. Eur Respir J 57(2):2002368CrossRefPubMed Barco S, Schmidtmann I, Ageno W, Anusic T, Bauersachs RM, Becattini C et al (2021) Survival and quality of life after early discharge in low-risk pulmonary embolism. Eur Respir J 57(2):2002368CrossRefPubMed
13.
go back to reference Barco S, Lankeit M, Binder H, Schellong S, Christ M, Beyer-Westendorf J et al (2017) Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Thromb Haemost 116(07):191–197 Barco S, Lankeit M, Binder H, Schellong S, Christ M, Beyer-Westendorf J et al (2017) Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Thromb Haemost 116(07):191–197
14.
go back to reference Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W et al (2014) Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation. Das Gesundheitswesen 77(01):53–61CrossRefPubMed Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W et al (2014) Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation. Das Gesundheitswesen 77(01):53–61CrossRefPubMed
15.
go back to reference Hobohm L, Anušić T, Konstantinides SV, Barco S (2020) Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) trial. Eur Respir J 56(4):2000663CrossRefPubMed Hobohm L, Anušić T, Konstantinides SV, Barco S (2020) Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) trial. Eur Respir J 56(4):2000663CrossRefPubMed
16.
go back to reference Bledsoe JR, Woller SC, Stevens SM, Aston V, Patten R, Allen T et al (2021) Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. Am J Emerg Med 41:80–83CrossRefPubMed Bledsoe JR, Woller SC, Stevens SM, Aston V, Patten R, Allen T et al (2021) Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. Am J Emerg Med 41:80–83CrossRefPubMed
17.
go back to reference Hendriks SV, Hout W, van Bemmel T, Bistervels IM, Eijsvogel M, Faber LM et al (2021) Home treatment compared to initial hospitalization in normotensive patients with acute pulmonary embolism in the netherlands: a cost analysis. Thromb Haemost 122:127–133 Hendriks SV, Hout W, van Bemmel T, Bistervels IM, Eijsvogel M, Faber LM et al (2021) Home treatment compared to initial hospitalization in normotensive patients with acute pulmonary embolism in the netherlands: a cost analysis. Thromb Haemost 122:127–133
18.
go back to reference Gustafsson N, Poulsen PB, Stallknecht SE, Dybro L, Paaske JS (2020) Societal costs of venous thromboembolism and subsequent major bleeding events: a national register-based study. Eur Heart J Qual Care Clin Outcomes 6(2):130–137CrossRefPubMed Gustafsson N, Poulsen PB, Stallknecht SE, Dybro L, Paaske JS (2020) Societal costs of venous thromboembolism and subsequent major bleeding events: a national register-based study. Eur Heart J Qual Care Clin Outcomes 6(2):130–137CrossRefPubMed
20.
go back to reference Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS et al (2017) Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study. Chest 151(5):1058–1068CrossRefPubMed Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS et al (2017) Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study. Chest 151(5):1058–1068CrossRefPubMed
21.
go back to reference Valerio L, Barco S, Jankowski M, Rosenkranz S, Lankeit M, Held M et al (2021) Quality of life three and twelve months after acute pulmonary embolism: analysis from a prospective multicenter cohort study. Chest 159:2428–2438CrossRefPubMed Valerio L, Barco S, Jankowski M, Rosenkranz S, Lankeit M, Held M et al (2021) Quality of life three and twelve months after acute pulmonary embolism: analysis from a prospective multicenter cohort study. Chest 159:2428–2438CrossRefPubMed
22.
go back to reference Fischer S, Meisinger C, Linseisen J, Berghaus TM, Kirchberger I (2023) Depression and anxiety up to two years after acute pulmonary embolism: prevalence and predictors. Thromb Res 222:68–74CrossRefPubMed Fischer S, Meisinger C, Linseisen J, Berghaus TM, Kirchberger I (2023) Depression and anxiety up to two years after acute pulmonary embolism: prevalence and predictors. Thromb Res 222:68–74CrossRefPubMed
23.
go back to reference Klok FA, Ageno W, Ay C, Back M, Barco S, Bertoletti L et al (2022) Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. Eur Heart J 43(3):183–189CrossRefPubMed Klok FA, Ageno W, Ay C, Back M, Barco S, Bertoletti L et al (2022) Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. Eur Heart J 43(3):183–189CrossRefPubMed
24.
go back to reference Boon G, Janssen SMJ, Barco S, Bogaard HJ, Ghanima W, Kroft LJM et al (2021) Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in post-PE syndrome. Thromb Res 206:66–75CrossRefPubMed Boon G, Janssen SMJ, Barco S, Bogaard HJ, Ghanima W, Kroft LJM et al (2021) Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in post-PE syndrome. Thromb Res 206:66–75CrossRefPubMed
25.
go back to reference Nopp S, Klok FA, Moik F, Petrovic M, Derka I, Ay C et al (2020) Outpatient pulmonary rehabilitation in patients with persisting symptoms after pulmonary embolism. J Clin Med 9(6):1811CrossRefPubMedPubMedCentral Nopp S, Klok FA, Moik F, Petrovic M, Derka I, Ay C et al (2020) Outpatient pulmonary rehabilitation in patients with persisting symptoms after pulmonary embolism. J Clin Med 9(6):1811CrossRefPubMedPubMedCentral
26.
go back to reference Willich SN, Chuang LH, van Hout B, Gumbs P, Jimenez D, Kroep S et al (2018) Pulmonary embolism in Europe—burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res 170:181–191CrossRefPubMed Willich SN, Chuang LH, van Hout B, Gumbs P, Jimenez D, Kroep S et al (2018) Pulmonary embolism in Europe—burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res 170:181–191CrossRefPubMed
Metadata
Title
Healthcare resource utilisation and associated costs after low-risk pulmonary embolism: pre-specified analysis of the Home Treatment of Pulmonary Embolism (HoT-PE) study
Authors
Ioannis T. Farmakis
Klaus Kaier
Lukas Hobohm
Katharina Mohr
Luca Valerio
Stefano Barco
Stavros V. Konstantinides
Harald Binder
Publication date
03-01-2024
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-023-02355-5

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now